DE60109943D1 - Inhibitoren der durch alpha 4 vermittelten zelladhäsion - Google Patents

Inhibitoren der durch alpha 4 vermittelten zelladhäsion

Info

Publication number: DE60109943D1
Authority: DE; Germany
Prior art keywords: inhibitors; alpha; cell adhesion; mediated cell; mediated
Prior art date: 2000-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60109943T

Other languages

English (en)

Other versions

DE60109943T2 (de

Inventor

Takayuki Kawaguchi

Sumihiro Nomura

Mikiko Tsukimoto

Toshiyuki Kume

Ila Sircar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tanabe Seiyaku Co Ltd

Original Assignee

Tanabe Seiyaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2001-08-27

Publication date

2005-05-12

2001-08-27 Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd

2005-05-12 Application granted granted Critical

2005-05-12 Publication of DE60109943D1 publication Critical patent/DE60109943D1/de

2006-02-09 Publication of DE60109943T2 publication Critical patent/DE60109943T2/de

2021-08-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Oncology (AREA)

DE60109943T 2000-08-31 2001-08-27 Inhibitoren der durch alpha 4 vermittelten zelladhäsion Expired - Lifetime DE60109943T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22912800P	2000-08-31	2000-08-31
US229128P		2000-08-31
PCT/US2001/026594 WO2002018320A2 (en)	2000-08-31	2001-08-27	INHIBITORS OF α4 MEDIATED CELL ADHESION

Publications (2)

Publication Number	Publication Date
DE60109943D1 true DE60109943D1 (de)	2005-05-12
DE60109943T2 DE60109943T2 (de)	2006-02-09

Family

ID=22859926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60109943T Expired - Lifetime DE60109943T2 (de)	2000-08-31	2001-08-27	Inhibitoren der durch alpha 4 vermittelten zelladhäsion

Country Status (28)

Country	Link
US (6)	US7026501B2 (de)
EP (1)	EP1315694B1 (de)
JP (1)	JP3899022B2 (de)
KR (1)	KR100528049B1 (de)
CN (1)	CN1229334C (de)
AR (1)	AR034556A1 (de)
AT (1)	ATE292615T1 (de)
AU (2)	AU2001286778B2 (de)
BR (1)	BR0113629A (de)
CA (1)	CA2418054C (de)
CZ (1)	CZ303460B6 (de)
DE (1)	DE60109943T2 (de)
DK (1)	DK1315694T3 (de)
ES (1)	ES2240509T3 (de)
HK (1)	HK1052684B (de)
HU (1)	HUP0302693A3 (de)
IL (2)	IL154305A0 (de)
MX (1)	MXPA03001837A (de)
MY (1)	MY129000A (de)
NO (1)	NO327861B1 (de)
NZ (1)	NZ524043A (de)
PL (1)	PL206656B1 (de)
PT (1)	PT1315694E (de)
RU (1)	RU2250895C2 (de)
SI (1)	SI1315694T1 (de)
TW (1)	TWI224587B (de)
WO (1)	WO2002018320A2 (de)
ZA (1)	ZA200301039B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60143984D1 (de)	2000-08-18	2011-03-17	Ajinomoto Kk	Neue phenylalanin-derivate
TWI312347B (en)	2001-02-08	2009-07-21	Eisai R&D Man Co Ltd	Bicyclic nitrogen-containing condensed ring compounds
JP4206273B2 (ja)	2001-04-27	2009-01-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	ピラゾロ［１，５−ａ］ピリジン化合物およびその医薬
MY140707A (en) *	2002-02-28	2010-01-15	Mitsubishi Tanabe Pharma Corp	Process for preparing a phenylalanine derivative and intermediates thereof
PL374971A1 (en)	2002-08-09	2005-11-14	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
US7176216B2 (en)	2002-10-22	2007-02-13	Eisai Co., Ltd.	7-phenylpyrazolopyridine compounds
KR100984085B1 (ko) *	2002-10-22	2010-09-30	에자이 알앤드디 매니지먼트 가부시키가이샤	7-페닐 피라졸로피리딘 화합물
JP2007501844A (ja)	2003-08-08	2007-02-01	トランス　テック　ファーマ，インコーポレイテッド	アリール及びヘテロアリール化合物、組成物並びに使用方法
WO2005014532A1 (en) *	2003-08-08	2005-02-17	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
RU2390520C2 (ru) *	2003-12-22	2010-05-27	Адзиномото Ко., Инк.	Новые производные фенилаланина
MY140489A (en)	2003-12-26	2009-12-31	Eisai R&D Man Co Ltd	1,2-di (cyclic) substituted benzene compounds
US7410971B2 (en)	2003-12-26	2008-08-12	Eisai R&D Management Co., Ltd.	1,2-di(cyclic)substituted benzene compounds
US7419666B1 (en)	2004-02-23	2008-09-02	Massachusetts Eye And Ear Infirmary	Treatment of ocular disorders
KR101274879B1 (ko)	2004-12-20	2013-06-14	에자이 알앤드디 매니지먼트 가부시키가이샤	1-시클로프로필메틸-4-[2-(3,3,5,5-테트라메틸시클로헥실)페닐]피페라진의 염 및 결정
NZ563739A (en)	2005-06-09	2009-12-24	Ucb Pharma Sa	2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament
CN101360711A (zh) *	2005-11-23	2009-02-04	阿斯利康(瑞典)有限公司	L-苯丙氨酸衍生物及其作为整联蛋白拮抗剂的用途
PT1984344E (pt) *	2005-12-29	2012-12-21	Lexicon Pharmaceuticals Inc	Derivados de aminoácidos multicíclicos e métodos para a sua utilização
US7897763B2 (en)	2005-12-29	2011-03-01	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
IL172896A0 (en) *	2005-12-29	2006-06-11	Yeda Res & Dev	Cxcr4 inhibition
US7855291B2 (en)	2005-12-29	2010-12-21	Lexicon Pharmaceuticals, Inc.	Process for the preparation of substituted phenylalanines
WO2007092471A2 (en) *	2006-02-03	2007-08-16	The Regents Of The University Of California	Methods for inhibition of lymphangiogenesis and tumor metastasis
CN101379028A (zh) *	2006-02-09	2009-03-04	阿斯利康(瑞典)有限公司	化学化合物
CA2641160A1 (en) *	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
PL2676967T3 (pl) *	2006-02-28	2019-12-31	Biogen Ma Inc.	Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
EP1991267B1 (de) *	2006-03-03	2017-12-20	Biogen MA Inc.	Verfahren zur behandlung von entzündungs- und autoimmunerkrankungen mit natalizumab
RU2493156C2 (ru) *	2007-08-24	2013-09-20	Лексикон Фармасьютикалз, Инк.	Способы получения соединений на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина
KR101601994B1 (ko)	2008-04-15	2016-03-17	에자이 알앤드디 매니지먼트 가부시키가이샤	3-페닐피라졸로[5,1-ｂ]티아졸 화합물
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
AU2010309891A1 (en)	2009-10-21	2012-05-17	Glaxo Group Limited	Process for preparing a phenylalanine derivative
US11287423B2 (en)	2010-01-11	2022-03-29	Biogen Ma Inc.	Assay for JC virus antibodies
ES2930469T3 (es)	2010-01-11	2022-12-14	Biogen Ma Inc	Ensayo para anticuerpos contra el virus jc
WO2012166971A2 (en)	2011-05-31	2012-12-06	Biogen Idec Ma Inc.	Method of assessing risk of pml
WO2013126595A1 (en) *	2012-02-21	2013-08-29	Massachusetts Eye And Ear Infirmary	Methods for treating corneal and conjunctival inflammation and inflammatory disorders
US10119976B2 (en)	2013-05-28	2018-11-06	Biogen Ma Inc.	Method of assessing risk of PML
WO2018085552A1 (en) *	2016-11-02	2018-05-11	Saint Louis University	Integrin antagonists
FI3873884T3 (fi)	2018-10-30	2025-02-24	Gilead Sciences Inc	3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7214882B2 (ja)	2018-10-30	2023-01-30	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
JP7189368B2 (ja)	2018-10-30	2022-12-13	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４ベータ７インテグリンの阻害のための化合物
US11179383B2 (en)	2018-10-30	2021-11-23	Gilead Sciences, Inc.	Compounds for inhibition of α4β7 integrin
CN119431230A (zh)	2019-08-14	2025-02-14	吉利德科学公司	用于抑制α4β7整合素的化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK148576A (da)	1975-04-18	1976-10-19	Boehringer Mannheim Gmbh	Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
US5780498A (en)	1993-11-01	1998-07-14	Ciba-Geigy Japan Limited	Endothelin receptor antagonists
WO1995026360A1 (en)	1994-03-28	1995-10-05	Japat Ltd.	Antagonists of endothelin receptors
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
JPH11505522A (ja)	1995-04-21	1999-05-21	ノバルティス・アクチエンゲゼルシャフト	エンドセリン阻害剤としてのｎ−アロイルアミノ酸アミド
CA2291778A1 (en)	1997-05-29	1998-12-03	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
EP1017382B1 (de)	1997-05-29	2006-03-01	Merck & Co., Inc. (a New Jersey corp.)	Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
JP2002501537A (ja)	1997-05-29	2002-01-15	メルクエンドカンパニーインコーポレーテッド	細胞接着阻害薬としてのスルホンアミド類
WO1998054207A1 (en)	1997-05-30	1998-12-03	Celltech Therapeutics Limited	Anti-inflammatory tyrosine derivatives
US6482849B1 (en)	1997-06-23	2002-11-19	Tanabe Seiyaku Co., Ltd.	Inhibitors of α4β1 mediated cell adhesion
AR016133A1 (es)	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
CA2291473A1 (en)	1997-07-31	1999-02-11	Elan Pharmaceuticals, Inc.	Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022406A (ko)	1997-07-31	2001-03-15	진 엠. 듀발	Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
EP1001972A1 (de)	1997-07-31	2000-05-24	Elan Pharmaceuticals, Inc.	Substituierte phenylalanin-derivate, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
CN1265674A (zh)	1997-07-31	2000-09-06	伊兰药品公司	能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
AR016387A1 (es)	1997-07-31	2001-07-04	Athena Neurosciences Inc	Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
AU8823498A (en)	1997-07-31	1999-02-22	American Home Products Corporation	Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
EP1001973A1 (de)	1997-07-31	2000-05-24	Elan Pharmaceuticals, Inc.	Verbindungen, die die vla-4 vermittelte adhäsion von leukozyten inhibieren
ATE260243T1 (de)	1997-08-22	2004-03-15	Hoffmann La Roche	N-aroylphenylalaninderivate
YU9600A (sh)	1997-08-22	2002-03-18	F. Hoffmann-La Roche Ag.	Derivati n-alkanoilfenilalanina
US6191171B1 (en)	1997-11-20	2001-02-20	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
AU1463499A (en)	1997-11-21	1999-06-15	Merck & Co., Inc.	Substituted pyrrole derivatives as cell adhesion inhibitors
DE69824037T2 (de)	1997-11-24	2005-06-02	Merck & Co., Inc.	Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6271252B1 (en)	1997-11-24	2001-08-07	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
US6197794B1 (en)	1998-01-08	2001-03-06	Celltech Therapeutics Limited	Phenylalanine derivatives
MY153569A (en) *	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
US6555562B1 (en)	1998-02-26	2003-04-29	Celltech R&D Limited	Phenylalanine derivatives
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
GB9811159D0 (en)	1998-05-22	1998-07-22	Celltech Therapeutics Ltd	Chemical compounds
GB9812088D0 (en)	1998-06-05	1998-08-05	Celltech Therapeutics Ltd	Chemical compounds
WO1999064395A1 (en)	1998-06-11	1999-12-16	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en)	1998-06-23	2004-06-11	Upjohn Co	Inhibitors of alpha4beta1 mediated cell adhesion
AU2209500A (en)	1998-12-22	2000-07-12	Pharmacia & Upjohn Company	Inhibitors of alpha4beta1 mediated cell adhesion
GB2354440A (en)	1999-07-20	2001-03-28	Merck & Co Inc	Aryl amides as cell adhesion inhibitors
US6420418B1 (en)	1999-08-16	2002-07-16	Merck & Co., Inc.	Heterocycle amides as cell adhesion inhibitors
WO2001014328A2 (en)	1999-08-20	2001-03-01	Merck & Co., Inc.	Substituted ureas as cell adhesion inhibitors
US6469047B1 (en)	1999-09-24	2002-10-22	Genentech, Inc.	Tyrosine derivatives
EP1315696A1 (de)	2000-08-31	2003-06-04	Eli Lilly And Company	Acetylenische sulfonamid-derivate

2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 PT PT01966246T patent/PT1315694E/pt unknown
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/hu unknown
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/xx unknown
- 2001-08-27 DK DK01966246T patent/DK1315694T3/da active
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/ru not_active IP Right Cessation
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en active IP Right Grant
- 2001-08-27 IL IL15430501A patent/IL154305A0/xx unknown
- 2001-08-27 SI SI200130351T patent/SI1315694T1/xx unknown
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/ja not_active Expired - Fee Related
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 AT AT01966246T patent/ATE292615T1/de active
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 DE DE60109943T patent/DE60109943T2/de not_active Expired - Lifetime
- 2001-08-27 CN CNB018149871A patent/CN1229334C/zh not_active Expired - Fee Related
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/pt active Search and Examination
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/ko not_active IP Right Cessation
- 2001-08-27 AU AU8677801A patent/AU8677801A/xx active Pending
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 PL PL365668A patent/PL206656B1/pl unknown
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/es active IP Right Grant
- 2001-08-27 EP EP01966246A patent/EP1315694B1/de not_active Expired - Lifetime
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/cs not_active IP Right Cessation
- 2001-08-27 ES ES01966246T patent/ES2240509T3/es not_active Expired - Lifetime
- 2001-08-31 TW TW090121581A patent/TWI224587B/zh not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/es active IP Right Grant
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/no not_active IP Right Cessation
- 2003-07-11 HK HK03105043.3A patent/HK1052684B/zh not_active IP Right Cessation
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7456217B2 (en)	2008-11-25
RU2250895C2 (ru)	2005-04-27
US7872151B2 (en)	2011-01-18
CA2418054A1 (en)	2002-03-07
MY129000A (en)	2007-03-30
HUP0302693A2 (hu)	2003-12-29
IL154305A0 (en)	2003-09-17
ATE292615T1 (de)	2005-04-15
KR100528049B1 (ko)	2005-11-15
DE60109943T2 (de)	2006-02-09
PL206656B1 (pl)	2010-09-30
AR034556A1 (es)	2004-03-03
CZ303460B6 (cs)	2012-09-26
HK1052684A1 (en)	2003-09-26
US7026501B2 (en)	2006-04-11
CZ2003487A3 (cs)	2003-06-18
AU2001286778B2 (en)	2005-02-10
PT1315694E (pt)	2005-07-29
CN1229334C (zh)	2005-11-30
US7671090B2 (en)	2010-03-02
ES2240509T3 (es)	2005-10-16
SI1315694T1 (en)	2005-10-31
US8501809B2 (en)	2013-08-06
US20050282900A1 (en)	2005-12-22
NO327861B1 (no)	2009-10-05
BR0113629A (pt)	2003-07-22
CA2418054C (en)	2008-08-05
IL154305A (en)	2010-11-30
NZ524043A (en)	2004-08-27
US20090111879A1 (en)	2009-04-30
US20030176498A1 (en)	2003-09-18
US20100113820A1 (en)	2010-05-06
KR20030059099A (ko)	2003-07-07
WO2002018320A3 (en)	2002-06-06
DK1315694T3 (da)	2005-08-08
TWI224587B (en)	2004-12-01
JP3899022B2 (ja)	2007-03-28
MXPA03001837A (es)	2003-10-15
WO2002018320A2 (en)	2002-03-07
HUP0302693A3 (en)	2005-05-30
AU8677801A (en)	2002-03-13
NO20030885D0 (no)	2003-02-25
JP2004507519A (ja)	2004-03-11
US20110077299A1 (en)	2011-03-31
EP1315694A2 (de)	2003-06-04
ZA200301039B (en)	2004-02-09
PL365668A1 (en)	2005-01-10
EP1315694B1 (de)	2005-04-06
CN1449377A (zh)	2003-10-15
US20130289109A1 (en)	2013-10-31
HK1052684B (zh)	2005-07-22
NO20030885L (no)	2003-02-25

Publication	Publication Date	Title
DE60109943D1 (de)	2005-05-12	Inhibitoren der durch alpha 4 vermittelten zelladhäsion
DE69932032D1 (de)	2006-08-03	Inhibitoren der alpha4 vermittelten zelladhäsion
DK0842944T3 (da)	2003-10-27	Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4
NO20003808L (no)	2000-09-26	Substituerte oksoazaheterosyklylfaktor Xa inhibitorer
AR028253A1 (es)	2003-04-30	Inhibidores de la glucogeno fosforilasa
NO975244L (no)	1998-05-18	5-ring-heterocykluser som inhibitorer av leukosyttadhesjon og VLA-4-antagonister
NO20011293D0 (no)	2001-03-14	Faktor VIIa-inhibitorer
DK0842945T3 (da)	2003-06-10	Heterocykliske forbindelser som inhibitorer af leukocytadhæsionen og VLA-4-antagonister
ATE383769T1 (de)	2008-02-15	Inhibitoren des transkriptionsfaktors nf-kappa b
NO980097D0 (no)	1998-01-09	Celleadhesjonsinhibitorer
DK1344524T3 (da)	2006-10-30	Refluksinhibitorer
ID26925A (id)	2001-02-22	Inhibitor-inhibitor metalloproteasa hidroksimata pirrolidina yang tersubstitusi
DE59708269D1 (de)	2002-10-24	Cyclische adhäsionsinhibitoren
PT1189929E (pt)	2003-12-31	Inibidores do factor viia
ATE252547T1 (de)	2003-11-15	Matrixmetalloproteinaseinhibitoren
ATE411995T1 (de)	2008-11-15	Inhibitoren der alpha-l-beta-2- integrinvermittelten zelladhäsion
ATE277023T1 (de)	2004-10-15	Indanderivate und ihre verwendung als zelladhäsionsinihibitoren
DK1130214T3 (da)	2005-08-29	Korrosionsinhibitorer
DK1307455T3 (da)	2005-07-25	Inhibitorer af alpha-L-beta-2-medieret celleadhæsion
FI943259A0 (fi)	1994-07-08	Soluadheesion peptidi-inhibiittorit
ITMO20020075A1 (it)	2003-09-29	Struttura muraria di forni, in particolare per l'industria ceramica,ed elemento strutturale relativo

Legal Events

Date	Code	Title	Description
2006-05-18	8364	No opposition during term of opposition